I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| CD8-positive, alpha-beta T cell | 3 studies | 22% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| CD8-positive, alpha-beta T cell | 3 studies | 22% ± 3% |
Insufficient scRNA-seq data for expression of CXCL13 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 48% | 66.52 | 277 / 578 | 82% | 139.73 | 942 / 1155 |
| stomach | 67% | 150.50 | 242 / 359 | 49% | 31.65 | 141 / 286 |
| prostate | 88% | 721.70 | 215 / 245 | 20% | 10.63 | 100 / 502 |
| spleen | 100% | 18175.00 | 241 / 241 | 0% | 0 | 0 / 0 |
| esophagus | 38% | 57.14 | 552 / 1445 | 56% | 35.15 | 103 / 183 |
| breast | 38% | 166.68 | 175 / 459 | 55% | 133.71 | 617 / 1118 |
| lymph node | 0% | 0 | 0 / 0 | 93% | 351.43 | 27 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 89% | 125.84 | 40 / 45 |
| uterus | 34% | 120.11 | 57 / 170 | 55% | 47.82 | 251 / 459 |
| intestine | 46% | 861.93 | 440 / 966 | 41% | 24.24 | 215 / 527 |
| skin | 23% | 14.83 | 410 / 1809 | 58% | 62.15 | 273 / 472 |
| bladder | 29% | 20.14 | 6 / 21 | 51% | 46.47 | 259 / 504 |
| liver | 57% | 713.88 | 128 / 226 | 19% | 14.26 | 76 / 406 |
| ovary | 31% | 36.78 | 55 / 180 | 34% | 11.51 | 145 / 430 |
| thymus | 26% | 142.20 | 173 / 653 | 27% | 21.21 | 163 / 605 |
| pancreas | 7% | 2.40 | 22 / 328 | 43% | 48.23 | 76 / 178 |
| kidney | 26% | 33.64 | 23 / 89 | 22% | 9.56 | 201 / 901 |
| brain | 24% | 17.31 | 625 / 2642 | 7% | 6.08 | 48 / 705 |
| adrenal gland | 25% | 10.21 | 64 / 258 | 5% | 3.42 | 11 / 230 |
| adipose | 24% | 32.16 | 293 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 13% | 10.45 | 179 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 12% | 14.79 | 111 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 4% | 1.59 | 3 / 80 |
| heart | 2% | 1.65 | 15 / 861 | 0% | 0 | 0 / 0 |
| muscle | 1% | 0.31 | 11 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0002544 | Biological process | chronic inflammatory response |
| GO_0006954 | Biological process | inflammatory response |
| GO_0035768 | Biological process | endothelial cell chemotaxis to fibroblast growth factor |
| GO_0090630 | Biological process | activation of GTPase activity |
| GO_0002467 | Biological process | germinal center formation |
| GO_0002518 | Biological process | lymphocyte chemotaxis across high endothelial venule |
| GO_0010820 | Biological process | positive regulation of T cell chemotaxis |
| GO_0030593 | Biological process | neutrophil chemotaxis |
| GO_0033634 | Biological process | positive regulation of cell-cell adhesion mediated by integrin |
| GO_0002920 | Biological process | regulation of humoral immune response |
| GO_0035754 | Biological process | B cell chemotaxis |
| GO_0007267 | Biological process | cell-cell signaling |
| GO_0045765 | Biological process | regulation of angiogenesis |
| GO_0006955 | Biological process | immune response |
| GO_0070098 | Biological process | chemokine-mediated signaling pathway |
| GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
| GO_0042742 | Biological process | defense response to bacterium |
| GO_0071222 | Biological process | cellular response to lipopolysaccharide |
| GO_2000545 | Biological process | negative regulation of endothelial cell chemotaxis to fibroblast growth factor |
| GO_0061844 | Biological process | antimicrobial humoral immune response mediated by antimicrobial peptide |
| GO_0033625 | Biological process | positive regulation of integrin activation |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0008201 | Molecular function | heparin binding |
| GO_0048248 | Molecular function | CXCR3 chemokine receptor binding |
| GO_0008009 | Molecular function | chemokine activity |
| GO_0048018 | Molecular function | receptor ligand activity |
| GO_0031724 | Molecular function | CXCR5 chemokine receptor binding |
| GO_0031735 | Molecular function | CCR10 chemokine receptor binding |
| GO_0045236 | Molecular function | CXCR chemokine receptor binding |
| GO_0017134 | Molecular function | fibroblast growth factor binding |
| Gene name | CXCL13 |
| Protein name | Alternative protein CXCL13 C-X-C motif chemokine C-X-C motif chemokine 13 (Angie) (B cell-attracting chemokine 1) (BCA-1) (B lymphocyte chemoattractant) (CXC chemokine BLC) (Small-inducible cytokine B13) |
| Synonyms | SCYB13 BCA1 hCG_22991 BLC |
| Description | FUNCTION: Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils. Does not induce calcium release in B-lymphocytes. Binds to BLR1/CXCR5. |
| Accessions | ENST00000286758.4 ENST00000682537.1 O43927 Q53X90 L8E878 |
